Evidence map›Paper›PMID 33627769›Full record

ArticleScientific reports2021

MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.

Wenrui Duan, Shirley Tang, Li Gao, Kathleen Dotts, Andrew Fink, Arjun Kalvala, Brittany Aguila, Qi-En Wang, Miguel A Villalona-Calero

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wenrui DuanDepartment of Human and Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, 33199, USA. wduan@fiu.edu.
Shirley TangComprehensive Cancer Center at The Ohio State University College of Medicine and Public Health, Columbus, OH, 43210, USA.
Li GaoDepartment of Human and Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, 33199, USA.
Kathleen DottsComprehensive Cancer Center at The Ohio State University College of Medicine and Public Health, Columbus, OH, 43210, USA.
Andrew FinkComprehensive Cancer Center at The Ohio State University College of Medicine and Public Health, Columbus, OH, 43210, USA.
Arjun KalvalaComprehensive Cancer Center at The Ohio State University College of Medicine and Public Health, Columbus, OH, 43210, USA.
Brittany AguilaComprehensive Cancer Center at The Ohio State University College of Medicine and Public Health, Columbus, OH, 43210, USA.
Qi-En WangDepartment of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Miguel A Villalona-CaleroDepartment of Human and Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, 33199, USA. mvillalona@coh.org.
The Ohio State University · USFlorida International University · US

Funding

Targeting Somatic Homologous Recombination in Solid TumorsR01CA152101 · NCI · OHIO STATE UNIVERSITY · PI VILLALONA, MIGUEL A · 2010 to 2014
$2.3M
Discovery of Homologous Recombination DNA Repair Deficiency in Lung TumorR21CA181291 · NCI · OHIO STATE UNIVERSITY · PI DUAN, WENRUI · 2014 to 2015
$368k
NCI NIH HHS R01 CA152101NCI NIH HHS R21 CA181291
6 · The paper itself

Abstract

The Fanconi Anemia (FA) pathway is essential for human cells to maintain genomic integrity following DNA damage. This pathway is involved in repairing damaged DNA through homologous recombination. Cancers with a defective FA pathway are expected to be more sensitive to cross-link based therapy or PARP inhibitors. To evaluate downstream effectors of the FA pathway, we studied the expression of 734 different micro RNAs (miRNA) using NanoString nCounter miRNA array in two FA defective lung cancer cells and matched control cells, along with two lung tumors and matched non-tumor tissue samples that were deficient in the FA pathway. Selected miRNA expression was validated with real-time PCR analysis. Among 734 different miRNAs, a cluster of microRNAs were found to be up-regulated including an important cancer related micro RNA, miR-200C. MiRNA-200C has been reported as a negative regulator of epithelial-mesenchymal transition (EMT) and inhibits cell migration and invasion by promoting the upregulation of E-cadherin through targeting ZEB1 and ZEB2 transcription factors. miRNA-200C was increased in the FA defective lung cancers as compared to controls. AmpliSeq analysis showed significant reduction in ZEB1 and ZEB2 mRNA expression. Our findings indicate the miRNA-200C potentially play a very important role in FA pathway downstream regulation.

Indexed as

A549 CellsCadherinsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFanconi AnemiaGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansLung NeoplasmsMicroRNAsSignal TransductionUp-RegulationZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2CadherinsHomeodomain ProteinsMicroRNAsZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2

Identifiers

PMID33627769
PMCPMC7904768
OpenAlexW3131539356

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.